Mesalazine inhibits activation of transcription factor NF-kappaB in inflamed mucosa of patients with ulcerative colitis.

Article Details

Citation

Bantel H, Berg C, Vieth M, Stolte M, Kruis W, Schulze-Osthoff K

Mesalazine inhibits activation of transcription factor NF-kappaB in inflamed mucosa of patients with ulcerative colitis.

Am J Gastroenterol. 2000 Dec;95(12):3452-7.

PubMed ID
11151876 [ View in PubMed
]
Abstract

OBJECTIVES: The salicylate mesalazine is commonly used for the treatment of inflammatory bowel diseases, yet its precise mechanism of action is unknown. Because transcription factor NF-kappaB plays an important role in inflammatory bowel diseases, we investigated the effects of mesalazine therapy on NF-kappaB activation in patients with ulcerative colitis. METHODS: A total of 20 patients with moderately active ulcerative colitis received mesalazine for 8 wk. Biopsies were taken before and after drug administration and analyzed for NF-kappaB activation using an antibody specific for active NF-kappaB. RESULTS: In biopsies of active ulcerative colitis but not in noninflamed mucosa, activation of NF-kappaB was detected predominantly in macrophages. Mesalazine therapy resulted, in a strong abrogation of NF-kappaB activation in situ. CONCLUSIONS: Our results suggest that the therapeutic properties of mesalazine rely at least in part on the inhibition of NF-kappaB activation, resulting in the suppression of proinflammatory gene expression in the inflamed mucosa.

DrugBank Data that Cites this Article

Drug Targets
DrugTargetKindOrganismPharmacological ActionActions
Aminosalicylic acidInhibitor of nuclear factor kappa-B kinase subunit alphaProteinHumans
Unknown
Inhibitor
Details
MesalazineInhibitor of nuclear factor kappa-B kinase subunit alphaProteinHumans
Unknown
Inhibitor
Details
MesalazineInhibitor of nuclear factor kappa-B kinase subunit betaProteinHumans
Unknown
Inhibitor
Details